Project Grant R21HL175093
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $248K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $761,615 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of biological sex in the heterogeneity of Acute Respiratory Distress Syndrome (ARDS). The research team at Massachusetts General Hospital aims to determine how increased alveolar epithelial expression of Secretory Leukocyte Protease Inhibitor (SLPI) in females may increase epithelial glycocalyx resilience, leading to a...
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...
- This federal Project Grant award of $1,479,335.00 from the National Heart Lung and Blood Institute under CFDA 93.837 Cardiovascular Diseases Research aims to leverage observational data and advanced machine learning methods to address gaps in understanding and personalizing treatment for Acute Respiratory Distress Syndrome (ARDS). The key products and services to be delivered include: Developing improved methods for ARDS phenotyping using dynamic clinical data to better understand prognosis...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
- This federal Project Grant award, titled "RESILIENCE ENDOTYPE-DERIVATION THROUGH PARSIMONIOUS ANALYSIS AND CAUSAL INFERENCE OF RECOVERY FROM ACUTE RESPIRATORY DISTRESS SYNDROME (REPAIR-ARDS)", is funded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) in the amount of $674,351. The project aims to develop predictive models for early diagnosis of Acute Respiratory Distress Syndrome (ARDS) using protein biomarkers and clinical data, as...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $791,503 to Weill Medical College of Cornell University to conduct research on the role of the thrombin receptor protease activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS). The 4-year award, effective September 15, 2025, aims to investigate a previously unappreciated function of PAR1 in the lung lymphatic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $180,174 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia Research Institute. The grant will fund a study to develop a framework for designing the next generation of pediatric acute respiratory distress syndrome (ARDS) clinical trials. Key objectives include: 1) Comparing heterogeneity of treatment effect (HTE) analysis methodologies in a trial of pediatric...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project at Brigham & Women's Hospital Inc. to better understand changes in the pulmonary vasculature and their relationship to lung parenchyma using advanced CT imaging in patients with pulmonary hypertension and chronic obstructive pulmonary disease (COPD). The $812,189 award, with a project period from May 1, 2025 to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- This federal Project Grant award of $200,502 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project led by Dr. Narges Alipanah-Lechner at the University of California, San Francisco (UCSF). The project aims to identify metabolite and protein drivers of the evolution of Acute Respiratory Distress Syndrome (ARDS) subtypes, specifically the hyper-inflammatory and hypo-inflammatory forms. The research will utilize comprehensive...